CoChat

A survey of ex vivo/in vitro transduction efficiency of mammalian primary cells and cell lines with Nine natural adeno-associated virus (AAV1-9) and one engineered adeno-associated virus serotype

Open access

The DOI matches its Crossref record; 62 of the 63 references it cites were found in a registry or an index.

Abstract

Background: The ability to deliver a gene of interest into a specific cell type is an essential aspect of biomedical research. Viruses can be a useful tool for this delivery, particularly in difficult to transfect cell types. Adeno-associated virus (AAV) is a useful gene transfer vector because of its ability to mediate efficient gene transduction in numerous dividing and quiescent cell types, without inducing any known pathogenicity. There are now a number of natural for that designed AAV serotypes that each has a differential ability to infect a variety of cell types. Although transduction studies have been completed, the bulk of the studies have been done in vivo , and there has never been a comprehensive study of transduction ex vivo/in vitro . Methods: Each cell type was infected with each serotype at a multiplicity of infection of 100,000 viral genomes/cell and transduction was analyzed by flow cytometry + . Results: We found that AAV1 and AAV6 have the greatest ability to transduce a wide range of cell types, however, for particular cell types, there are specific serotypes that provide optimal transduction. Conclusions: In this work, we describe the transduction efficiency of ten different AAV serotypes in thirty-four different mammalian cell lines and primary cell types. Although these results may not be universal due to numerous factors such as, culture conditions and/ or cell growth rates and cell heterogeneity, these results provide an important and unique resource for investigators who use AAV as an ex vivo gene delivery vector or who work with cells that are difficult to transfect.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/1743-422x-10-74

Cites

62 of 62 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 A schematic representation of the self-complimentary AAV (scAAV) genome. We constructed a scAAV genome (double black lines) that included an eGFP reporter gene (in green) driven by the CMV promoter (black arrow) that allowed for efficient and quantitative analysis of transduction. This construct also included a poly A sequence (black line) and inverted terminal repeats (ITRs) in blue)).
Figure 1 A schematic representation of the self-complimentary AAV (scAAV) genome. We constructed a scAAV genome (double black lines) that included an eGFP reporter gene (in green) driven by the CMV promoter (black arrow) that allowed for efficient and quantitative analysis of transduction. This construct also included a poly A sequence (black line) and inverted terminal repeats (ITRs) in blue)).CC BY · PubMed Central
Figure 2 scAAV transduction of human primary and immortalized cells. A) Human primary cells and B) human immortalized cell lines were transduced with eGFP scAAV at a multiplicity of infection (MOI) of 100,000 viral genomes (vg)/ cell. The cells were analyzed by flow cytometry at 48 hours post-infection for the percentage that were GFP positive. The number in the box is the actual percentage of GFP positive cells with that serotype. * = Transduction less than 0.01% but greater than 0.0%.
Figure 2 scAAV transduction of human primary and immortalized cells. A) Human primary cells and B) human immortalized cell lines were transduced with eGFP scAAV at a multiplicity of infection (MOI) of 100,000 viral genomes (vg)/ cell. The cells were analyzed by flow cytometry at 48 hours post-infection for the percentage that were GFP positive. The number in the box is the actual percentage of GFP positive cells with that serotype. * = Transduction less than 0.01% but greater than 0.0%.CC BY · PubMed Central
Figure 3 scAAV transduction of murine primary cells and murine, hamster, and monkey immortalized cells. A) Murine primary cells and B) murine, hamster, and monkey immortalized cell lines were transduced with eGFP scAAV at a multiplicity of infection (MOI) of 100,000 vg/ cell. The cells were analyzed by flow cytometry at 48 hours post-infection for the percentage that were GFP positive. The number in the box is the actual percentage of GFP positive cells with that serotype.
Figure 3 scAAV transduction of murine primary cells and murine, hamster, and monkey immortalized cells. A) Murine primary cells and B) murine, hamster, and monkey immortalized cell lines were transduced with eGFP scAAV at a multiplicity of infection (MOI) of 100,000 vg/ cell. The cells were analyzed by flow cytometry at 48 hours post-infection for the percentage that were GFP positive. The number in the box is the actual percentage of GFP positive cells with that serotype.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 62 references

Cited by

See all 252

Metadata

Authors
Ellis, B. L., Hirsch, M. L., Barker, J. C., Connelly, J. P., Steininger, R. J., & Porteus, M. H.
Affiliations
  • The University of Texas Southwestern Medical Center (US)
  • University of North Carolina at Chapel Hill (US)
  • Harold C. Simmons Comprehensive Cancer Center (US)
Corresponding author
Porteus, Matthew H
Venue
Virology Journal
Published
2013-03-06
Volume
10
Issue
1
Pages
74-74
ISSN
1743-422X (ISSN-L)
OpenAlex
W2112808685
Cited by
252
References
63
Citations by year
2026: 21 · 2025: 32 · 2024: 25 · 2023: 24 · 2022: 27 · 2021: 28 · 2020: 20 · 2019: 22 · 2018: 10 · 2017: 15 · 2016: 7 · 2015: 11 · 2014: 7 · 2013: 1
FWCI
5.74
Type
journal article
Language
en
Open access
Licence
  • cc-by
  • creativecommons.org/licenses/by/2.0 (tdm)
Locations
  • Virology Journal (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion, cc-by)
  • Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
  • eScholarship (California Digital Library) (submittedVersion)
  • UNC Libraries
Funders
  • Amon G. Carter Foundation
  • University of Texas Southwestern Medical Center
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Viral Infectious Diseases and Gene Expression in Insects
Keywords
adeno-associated virus, AAV serotypes, AAV1, AAV6, AAV9, transduction efficiency, ex vivo gene delivery, in vitro gene transfer, mammalian cell lines, primary cells, viral vectors
MeSH terms
Dependovirus, Animals, Haplorhini, Cell Line, Cells, Cultured, Genetic Engineering, Genetic Vectors, Cricetinae, Humans, Mammals, Transduction, Genetic, Genetic Therapy, Mice, Viral Tropism

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A survey of ex vivo/in vitro transduction efficiency of mammalian primary cells and cell lines with Nine natural adeno-associated virus (AAV1-9) and one engineered adeno-associated virus serotype. https://app.cochat.ai/papers/10.1186/1743-422x-10-74
The paper
Ellis, B. L., Hirsch, M. L., Barker, J. C., Connelly, J. P., Steininger, R. J., & Porteus, M. H. (2013). A survey of ex vivo/in vitro transduction efficiency of mammalian primary cells and cell lines with Nine natural adeno-associated virus (AAV1-9) and one engineered adeno-associated virus serotype. Virology Journal. https://doi.org/10.1186/1743-422x-10-74

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.